论文部分内容阅读
目的分析研讨米非司酮在子宫肌瘤疾病治疗中的临床效果。方法此研究为前瞻性研究,采用随机抽签方式,从我院2015年3月-2016年2月期间收治的子宫肌瘤患者中,抽取120例纳入到讨论中,120例按入院单双顺序号分60例对照组(手术前不接受任何药物干预)和60例研究组(术前三个月接受米非司酮药物治疗),对比两组患者治疗状况。结果对比其服药前肌瘤体积,组间数据无统计学意义(P>0.05);对比其服药后肌瘤体积,组间数据有统计学意义(P<0.05)。对比研究组EG FR+、ER+计分状况,组间数据有统计学意义(P<0.05);对比其不良反应发生率,研究组3.33%比对照组71.67%低,组间数据有统计学意义(P<0.05)。结论术前给予子宫肌瘤患者米非司酮药物干预,可显著缩小子宫肌瘤,且EGFR+、ER+改善明显,应用性和推广性较大。
Objective To analyze the clinical effect of mifepristone in the treatment of uterine myoma diseases. METHODS: This study was a prospective study. Randomized draws were taken from 120 patients with uterine fibroids admitted from March 2015 to February 2016 in our hospital. 120 patients were enrolled in the study. The control group (60 cases without any drug intervention) and 60 cases (receiving mifepristone three months before surgery) were divided into two groups to compare the treatment status of the two groups. Results Compared with the volume of myoma before administration, the data of the two groups were not statistically significant (P> 0.05). The data of EG FR + and ER + scoring in the study group were statistically significant (P <0.05). Compared with the incidence of adverse reactions, the study group was 3.33% lower than the 71.67% in the control group with statistical significance P <0.05). Conclusion The intervention of mifepristone in patients with uterine fibroids preoperatively can significantly reduce uterine fibroids, and the improvement of EGFR +, ER + is obvious.